The text starts here.


Eisai’s affiliates in China are a pharmaceutical company wholly-owned by Eisai Co., Ltd. (hereinafter referred to as 'Eisai'), a Japanese multinational pharmaceutical company headquartered in Tokyo with R&D of pharmaceutical products as main business. In 2017, Eisai Co., Ltd. achieved a total sales of 600.1 billion yen, with the overseas sales including export business reaching 243.5 billion yen. Its pharmaceutical sales in Asia including China region reached 84.0 billion yen, increasing by 101% year-on-year, making Asia the region leading the fast growth of the Group.

Eisai has a long history of communication exchange with Chinese medical industry. In 1972, Beijing Medical University initiated communication with Eisai, and taking this opportunity, Eisai began to provide support for the academic communications between famous medical universities in China and Japan. After the normalization of diplomatic relations between China and Japan, Eisai's Chairman Yuji Naito was invited to visit China as one of the first group of representatives of top Japanese companies, and was appointed as honorary advisor of Beijing Medical University and the Japan Research Institute of Fudan University.

Thereafter, in 1991, Eisai established a Representative Office in Beijing and formed a joint venture company – Shenyang Eisai Pharmaceutical Co. Ltd. – to start sales and marketing activities in the field of cardiovasology. To better serve the needs of patients, Eisai established in 1996 Eisai (Suzhou) Pharmaceutical Co., Ltd, a pharmaceutical manufacturer in Suzhou. In 2002, Eisai (Suzhou) Pharmaceutical Co., Ltd. was renamed to Eisai China Inc. and increased its investments in the Suzhou factory to expand production capacity.

Currently, with specific focus on the fields of neurology, gastroenterology, liver diseases and endocrinology, orthopedics and oncology, Eisai China, Inc. realizes local production of seven products and subpackaging of five other products. The company employed nearly 1,000 medical representatives in the whole China in 2017, carrying out marketing and promoting activities in 4,800 hospitals in over 100 cities with a population of over 1 million. In 2017, Eisai China, Inc. was ranked No. 1 among the Japanese pharmaceutical manufacturers in China in terms of sales amount.

The hhc corporate philosophy of Eisai is to give top priority to the benefit of patients and their families and contribute to enhancing their well-being. Eisai includes the hhc philosophy into the Articles of Association and takes Compliance (complying with laws and regulations and ethics) as the basic codes of conduct for daily activities, dedicating to the fulfillment of corporate social responsibility.

In future, we will further reinforce our lines of strategic products, so as to better meet the needs of patients in China.

Kaneko Norio